Li Chen, PhD

Assistant Professor
Division of Cancer Biostatistics
Department of Biostatistics
College of Public Health and Biostatistics
Bioinformatics Shared Resource Facility
Markey Cancer Center
University of Kentucky, USA


Dr. Chen is an Assistant Professor of the Division of Cancer Biostatistics in the Department of Biostatistics and the Biostatistics and Bioinformatics Shared Resource Facility at the Markey Cancer Center, University of Kentucky. She received her PhD in Biostatistics from the University of North Carolina at Chapel Hill in 2009.

Research Interest

Her research interests includes: Development and application of novel statistical methods for medical and epidemiological studies especially in cancer research. Semiparametric and Nonparametric Methods, Survival Analysis, Longitudinal Data Analysis and Prediction Models.

Scientific Activities


• (2011)- Larry Kupper Dissertation Publication Award, Department of Biostatistics, University of North Carolina at Chapel Hill
• (2010 )- Barry H. Margolin Dissertation Award, Department of Biostatistics, University of North Carolina at Chapel Hill
• (2005)- Pass with Special Commendations in Qualifying Exams, Department of Biostatistics, University of North Carolina at Chapel Hill
• (2004 – 2005)- Merit Assistantship of University of North Carolina at Chapel Hill
• (2004)- Title of Outstanding Graduate of Peking University
• (2001 – 2003)- Canon Special Scholarship of Peking University
• (1999 – 2000)- NKK Scholarship of Peking University


• American Statistical Association
• Chinese Statistical Association


1. Chen L, Lin DY, Zeng D. Attributable fraction functions for censored event times. Biometrika. 2010; 97: 713-726. doi: 10.1093/biomet/asq023
2. Davison BA, Cotter G, Sun H, et al. Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. Clin Res Cardiol. 2011; 100(9): 745-753. doi:10.1007/s00392-011-0304-5.
3. Chen L, Lin DY, Zeng D. Predictive accuracy of covariates for event times. Biometrika. 2012; 99(3): 615-630. doi:10.1093/biomet/ass018
4. Chen L, Lin DY, Zeng D. Checking transformation models with censored data. Biostatistics. 2012; 13(1): 18-31. doi:10.1093/biostatistics/kxr017
5. Chen L, Romond E, Chokshi S, et al. A prognostic model of early breast cancer relapse after standard adjuvant therapy and comparison with metastatic disease on initial presentation. Breast Cancer Res Treat. 2012; 136(2): 565-572. doi:10.1007/s10549-012-2265-4.
6. Feddock J, Arnold SM, Shelton BJ, et al. Stereotactic body radiotherapy (SBRT) can be used safely to boost residual disease in locally advanced non-small cell lung cancer (NSCLC): a prospective study. Int J Radiat Oncol Biol Phys. 2013; 85(5): 1325-1331. doi: 10.1016/j.ijrobp.2012.11.011.
7. Sui X, Li H, Zhang J, Chen L, Zhu L, Blair SN. Percentage of Deaths Attributable to Poor Cardiovascular Health Lifestyle Factors: Findings from the Aerobics Center Longitudinal Study. Epidemiology Research International. 2013; 2013. Article ID 437465. doi:10.1155/2013/437465
8. Shang Y, Lin Y, Henry BA, et al. Noninvasive evaluation of electrical stimulation impacts on muscle hemodynamics via integrating diffuse optical spectroscopies with muscle stimulator. Journal of biomedical optics. 2013; 18(10): 105002-105002. doi:10.1117/1.JBO.18.10.105002.
9. Feddock J, Cleary R, Arnold S, et al. McGarry RC. Risk for fatal pulmonary hemorrhage does not appear to be increased following dose escalation using Stereotactic Body Radiotherapy (SBRT) in Locally Advanced Non-Small Cell Lung Cancer. Journal of Radiosurgery and SBRT. 2013; 2(3): 235-242.
10. McGarry RC, Feddock J, Sinha P, et al. Early postchemoradiation PET/CT for assessing responses of stage II-III non-small cell lung cancer to treatment. Journal of Radiosurgery and SBRT. 2013; 2(4): 315-323.
11. Chen L, Voronovich Z, Clark K, et al. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro-Oncology. 2014; 16(11):1478-1483. doi:10.1093/neuonc/nou097.
12. Chen A, Chen L, Al-Qaisi A, et al. Everolimus-induced hematologic changes in patients with metastatic breast cancer. Clinical Breast Cancer. 2014. doi:10.1016/j.clbc.2014.07.002.
13. Alqaisi A, Chen L, Romond E, Stevens M, Pasley G, Massarweh S. Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: Implications for tumor biology and research. Breast Cancer Res Treat. 2014; 148(2):437-444. doi:10.1007/s10549-014-3145-x.